Want to see SE:SCIB full AI Analyst Report?
SCIB Stock Chart & Stats
kr0.33
>-kr0.01(-1.65%)
At close: 4:00 PM EST
kr0.33
>-kr0.01(-1.65%)
Day’s Range― - ―
52-Week Rangekr16.67 - kr54.00
Previous CloseN/A
Volume1.41K
Average Volume (3M)318.73K
Market Cap
kr304.71M
Enterprise Valuekr239.58
Total Cash (Recent Filing)kr71.25M
Total Debt (Recent Filing)kr23.93M
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.94
Shares Outstanding10,225,300
10 Day Avg. Volume218,776
30 Day Avg. Volume318,725
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)18.68
Price to Sales (P/S)3.07
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.33
Revenue Forecast (FY)kr65.90M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent top-line expansion indicates growing clinical adoption of the Nevisense platform. Durable revenue growth supports expanding installed base and recurring per-test revenue, improving prospects for scaling fixed-cost absorption and eventual path to operating leverage.
Gross MarginA ~59% gross margin implies attractive unit economics for device and consumable sales. Sustained margin cushions operating losses while revenue scales, enabling the company to invest in commercial expansion without immediate margin erosion and supports long-term profitability potential.
Manageable LeverageModerate debt relative to equity and positive net assets provide financial flexibility. Manageable leverage reduces near-term solvency risk and makes external funding or refinancing easier if required to support growth, lowering structural bankruptcy risk versus highly leveraged peers.
Bears Say
Very Large Operating LossesOperating and net margins that are deeply negative show the cost base far exceeds current revenues, indicating the business is not near break-even. Persistent structural losses increase dependence on external capital and raise long-term execution risk if revenue scaling slows.
Weak Cash GenerationDeeply negative operating and free cash flow reflect ongoing cash burn to fund commercialization. This structural cash shortfall forces reliance on dilutive financing or debt, constraining strategic optionality and potentially delaying investments if capital access tightens.
Equity Volatility / Dilution RiskHistorical swings in equity and notably low equity in 2025 suggest past financing and dilution events. Continued losses make further equity raises likely, diluting shareholders and signaling ongoing funding risk that can impair long-term investor returns and strategic continuity.
SciBase Holding AB News
SCIB FAQ
What was SciBase Holding AB’s price range in the past 12 months?
SciBase Holding AB lowest stock price was kr16.67 and its highest was kr54.00 in the past 12 months.
What is SciBase Holding AB’s market cap?
SciBase Holding AB’s market cap is kr304.71M.
When is SciBase Holding AB’s upcoming earnings report date?
SciBase Holding AB’s upcoming earnings report date is Aug 19, 2026 which is in 16 days.
How were SciBase Holding AB’s earnings last quarter?
SciBase Holding AB released its earnings results on May 07, 2026. The company reported -kr3 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is SciBase Holding AB overvalued?
According to Wall Street analysts SciBase Holding AB’s price is currently Overvalued.
Does SciBase Holding AB pay dividends?
SciBase Holding AB does not currently pay dividends.
What is SciBase Holding AB’s EPS estimate?
SciBase Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SciBase Holding AB have?
SciBase Holding AB has 10,225,300 shares outstanding.
What happened to SciBase Holding AB’s price movement after its last earnings report?
SciBase Holding AB reported an EPS of -kr3 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.618%.
Which hedge fund is a major shareholder of SciBase Holding AB?
Currently, no hedge funds are holding shares in SE:SCIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SciBase Holding AB
SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their key offerings, Nevisense and Nevisense Go, comprise a point-of-care platform designed for the detection of melanoma and non-melanoma skin cancers, as well as for evaluating skin barrier function. The company also maintains a collaborative agreement with the Advanced Dermatology and Cosmetic Surgery (ADCS) group.
Technical Analysis
Clinical Laserthermia Systems AB Class B
―
Luxbright AB
―
Arcoma AB
―
Neola Medical AB
―
Iconovo AB
―